Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181

Keloid Clinical Trial

Official title:

A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01446770
• Other study ID #: HAL-0127
• Status: Completed
• Phase: Phase 2
• First received: October 2, 2011
• Last updated: March 12, 2012
• Start date: November 2010
• Est. completion date: December 2011

Study information

• Verified date: March 2012
• Source: Halscion, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Government of Bahamas: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the initial safety and efficacy of MF-4181, a hydrogel scaffold, in the reduction of the volume, appearance, and/or symptoms associated with keloid scarring in subjects undergoing surgical revision of keloid scars.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 15 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male or female subjects 15 to 50 years of age each having at least one keloid scar on the ear. (If both ears have keloids, both ears may be treated with E-Matrix).

• Keloids that have not undergone more than two surgical revisions (laser, cryotherapy or surgery)

• Keloids that have been present for = 1 year.

• The keloid must measure = 0.5 cm and not extend onto other portions of the head, neck, or face.

• Able and willing to give written informed consent. (Age 15-17 must have written informed consent of legal guardian).

• Willing to comply with the follow up schedule for a minimum of 6 months.

Exclusion Criteria:

• Subjects with history of prior treatment at the study site or prior treatment of the keloid in the previous 6 weeks.

• Pregnant or planning to become pregnant during the course of the study.

• Heart disease or history of congestive heart failure.

• Advanced or poorly controlled diabetes.

• Current or history of heavy smoking (i.e., 10 pack years)

• Active local infection at the treatment site and/or systemic infection.

• History of or active central nervous system disease.

• History of fever, migraine headaches, and/or recurrent upper respiratory infection.

• Active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus, polyarthritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic purpura.

• Unwilling or unable to return for follow-up visits.

• Unwilling to refrain from use of any other scar treatment therapy/scar improving product, during the study, including steroid injections.

• Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid use in the area to be treated.

• Current participation or participation within the last 3 months in the study of an investigational drug, device, or biologic.

• Unable or unwilling to follow post-operative instructions.

• Known hypersensitivity to MF-4181, collagen, dextran, or any of its constituent materials.

• Known hypersensitivities to animal-based products

• Previous participation in this study to avoid multiple enrollments of an individual subject.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Keloid

Intervention

Device:
• Hydrogel scaffold (MF-4181)
Following surgical removal of the ear keloid, the incision will be treated with MF-4181.

Locations

Country	Name	City	State
Bahamas	Princess Margaret Hospital	Nassau

Sponsors (1)

Lead Sponsor	Collaborator
Halscion, Inc.

Country where clinical trial is conducted

Bahamas, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Device safety	Device safety is defined as the incidence of device related adverse events.	6 months	Yes
Secondary	Device efficacy	Evaluations of cosmesis, induration, erythema and pigmentation will be evaluated by the investigator.	12 months	No
Secondary	Device efficacy	Volume and linear measurements will be taken by the investigator	12 months	No
Secondary	Device efficacy	Subject evaluation of cosmesis, pain, tenderness, itching and scar satisfaction will be obtained.	12 months	No